Yüklüyor......
Phase I-II Study of Bendamustine in Patients With Acute Leukemia and High Risk Myelodysplastic Syndrome
A phase I-II study of bendamustine fractionated twice daily schedule for 4 days identified 75 mg/m(2) intravenously (IV) twice daily for 4 days as a phase II study schedule. BACKGROUND: Alkylating agents have shown activity in leukemia. Bendamustine, an active alkylating agent in lymphoma and chroni...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2012
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4050633/ https://ncbi.nlm.nih.gov/pubmed/22578814 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2012.03.004 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|